Sygnis (LIO1)

Business description

Sygnis develops polymerases for the amplification and sequencing of DNA. It launched a directly sold via web range of products in 2015, with more products due in 2016. It also uses distributors. Sygnis plans to acquire Expedeon, a proteomics business with direct sales capability.

Bigger, stronger, faster

QuickView | Pharmaceutical & healthcare | 09/11/2016

Following the acquisition of Expedeon, Sygnis expects to achieve profitability in 2017 if sales grow to about €7m; management is focused on achieving sales synergies and controlling costs. The acquisition was funded by issuing 20.54m shares at €1.10 each including a cash fundraising of €5.3m gross. Sygnis produces innovative molecular biology kits, while Expedeon makes well-designed products for protein analysis. Expedeon has a UK- and US-focused, 13-person sales and marketing team and a five-year sales CAGR of about 20%. Integration and sales training will take most of 2016. Guidance on sales is expected in November 2016.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news

Sygnis

Mon, 26 Jun 2017 10:07:30 GMT

Sygnis

Wed, 22 Jun 2016 23:00:16 GMT

Sygnis

Mon, 08 May 2017 10:52:30 GMT

Sygnis

Wed, 16 Aug 2017 03:22:30 GMT

Sygnis

Wed, 16 Aug 2017 03:22:30 GMT